User:Camille Gaudet/Sandbox 1

From Proteopedia

(Difference between revisions)

Revision as of 21:46, 28 April 2024

Glucose-dependent Insulinotropic Polypeptide Receptor

1 Introduction
- 1.1 History
- 1.2 Biological Role
2 General Structure
3 Associated Diseases
4 Medical Relevance
- 4.1 Tirzepatide Structure

Introduction

History

Investigation of pancreatic hormones began at the turn of the 20th century. In 1902, Bayliss and Starling discover a pancreatic secretin involved in regulation of water homeostasis, giving rise to interest in pancreatic hormones. Shortly after, in 1906, Moore et al. hypothesize involvement of gastrointestinal hormone extracts in maintenance of the endocrine pancreas. Jean La Barre purifies glucose-lowering gut extracts in 1929 and characterizes them as incretins, which is short for intestine secretion insulin. Finally, in 1984, gastric inhibitory peptide (GIP) is isolated from porcupine intestine. Although GIP was initially characterized for its gastric inhibitory effects (hence the name), it was also shown that the polypeptide played an integral role in insulin signaling and secretion. Interestingly, it was found that the effect of GIP on insulin levels was still seen in its absence, hinting toward the presence of an additional incretin, which has now been classified as glucagon-like peptide-1 (GLP-1).

Biological Role

Figure 1. The biological roles of GIP and and GLP-1, incretin hormones.

The GIP receptor (GIPR) helps facilitate the transport of glucose into/out of the cell through the stimulation of insulin secretion. ^[1]. GIPR is a type of G-Protein Coupled Receptor (GPCR), and its natural ligand, GIP, serves as an initiator of a cellular signaling cascade, thereby activating adenylyl cyclase and increasing cAMP levels. Subsequently, insulin secretion is stimulated. Insulin, a peptide hormone, is secreted by the pancreas in response to glucose ingestion, allowing intake of glucose into the cell via the Glut2 transporter. Notably, GIP, as well as GLP-1, serve a multitude of biological roles (Figure 1) other than insulin signaling.

General Structure

The Receptor and G Protein (GIPR)

appears as a typical G-Protein Coupled Receptor, containing a with seven helical passes and an , where the ligand binds. These two domains comprise the . Intracellularly, the receptor is bound to a G-Protein which is comprised by the , , and subunits, where the Beta and Gamma subunits typically dimerize. Upon binding of GIP to the receptor, the intracellular signaling cascade is initiated.

Glucose-dependent Insulinotropic Polypeptide

The binds to its receptor extracellularly, inserting itself N-terminus down into the transmembrane and extracellular domains of the GIP receptor. The polypeptide is 42 residues in length and takes on a helical structure.

Active Site

A crucial binding interaction within the active site occurs between and receptor residues W296 and Q224. The hydroxyl of the tyrosine residue forms a hydrogen bond to the amide of the glutamine, and the aromaticity of both the tyrosine and tryptophan residues results in pi stacking between them. In GIP agonist diabetes medications, conservation of the Tyr1 residue can determine the drug’s efficacy in initiating a GIP-like response.

Associated Diseases

In individuals with diabetes, insulin is improperly under-secreted or unresponsive to elevated blood glucose levels. Considering its role as the initial metabolite in glycolysis, when glucose is not effectively transported into the cell, it renders the body unable to successfully execute energy production through cellular respiration (Glycolysis --> the Krebs Cycle --> the Electron Transport Chain --> ATP synthesis).

Medical Relevance

Many anti-diabetes drugs exist for patients with both Type I and Type II diabetes, including a new dual GIP and GLP-1 agonist known as Tirzepatide (Brand Name: Mounjaro, Manufacturer: Lilly). Tirzepatide is capable of inducing the effects of both GIP and GLP-1 cellular signalling by mimicking each ligand and binding to their respective receptor. Increased presence (or, the apparent increased presence) of GIP and GLP-1 leads to enhanced stimulation of insulin secretion, thereby reducing blood glucose levels.

Tirzepatide Structure

Structurally, as a dual agonist, closely resembles GIP and GLP-1. The sequence alignment of all three polypeptides showcases the highly integrated nature of both GIP and GLP-1 into the amino acid sequence of Tirzepatide with very few alterations (Figure 2).

Figure 2. Sequence alignment of GLP-1, GIP, and Tirzepatide. Residues shown in black are found in all three amino acid sequences. Pink or red coloration denotes residues that are unique to GIP or GLP-1, respectively. The sequence of tirzepatide is colored accordingly, and residues differing from both GIP and GLP-1 are highlighted in blue. Residues that differ across all three structures are boxed.

The residue allows for simulation of a highly similar interaction between Tirzepatide and the GIP receptor. Had this been altered, Tirzepatide would not nearly bind with as high of an affinity for GIPR. Several do not align with either the sequence of GIP or GLP-1 and are located toward the C-terminus end of the structure. They include Ala21, Gln24, Ile27, and Gly30. The are Asp21, Asn24, Leu27, and Lys30. Interestingly, these residues do not interact with the receptor, thus their mutation doesn't alter the overall binding affinity of Tirzepatide to GIPR.

References

^[1]

↑ ^1.0 ^1.1 Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, Ho JD, Showalter AD, Stutsman C, Ding L, Suter TM, Dunbar JD, Carpenter JW, Mohammed FA, Aihara E, Brown RA, Bueno AB, Emmerson PJ, Moyers JS, Kobilka TS, Coghlan MP, Kobilka BK, Sloop KW. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2116506119. PMID:35333651 doi:10.1073/pnas.2116506119

Student Contributors

Camille Gaudet
Sara Kalkhoff

Proteopedia Page Contributors and Editors (what is this?)

Camille Gaudet

Retrieved from "http://52.214.119.220/wiki/index.php/User:Camille_Gaudet/Sandbox_1"

Revision as of 21:43, 28 April 2024 (edit) Camille Gaudet (Talk \| contribs) ← Previous diff		Revision as of 21:46, 28 April 2024 (edit) (undo) Camille Gaudet (Talk \| contribs) Next diff →
Line 29:		Line 29:

	=== Tirzepatide Structure===		=== Tirzepatide Structure===
-	Structurally, as a dual agonist, <scene name='10/1037488/Tirz-bound/3'>Tirzepatide</scene> closely resembles GIP and GLP-1. The sequence alignment of all three polypeptides showcases the highly integrated nature of both GIP and GLP-1 into the amino acid sequence of Tirzepatide, with very few alterations (Figure 2). [[Image:GIPGLPTirz.png\|700 px\|right\|thumb\|Figure 2. Sequence alignment of GLP-1, GIP, and Tirzepatide. Residues shown in black are found in all three amino acid sequences. Pink or red coloration denotes residues that are unique to GIP or GLP-1, respectively. The sequence of tirzepatide is colored accordingly, and residues differing from both GIP and GLP-1 are highlighted in blue. Residues that differ across all three structures are boxed.]] The <scene name='10/1037488/Gip-y1-intrxn-still/8'>conserved Tyr1</scene> residue allows for simulation of a highly similar interaction between Tirzepatide and the GIP receptor. Had this been altered, Tirzepatide would not nearly bind with as high of an affinity for GIPR. Several <scene name='10/1037488/Tirz-bound-differences/3'>unique residues in Tirzepatide</scene> do not align with either the sequence of GIP or GLP-1 and are located toward the C-terminus end of the structure. They include Ala21, Gln24, Ile27, and Gly30. The <scene name='10/1037488/Gip-differences/6'>corresponding GIP residues</scene> are Asp21, Asn24, Leu27, and Lys30. Interestingly, these residues do not interact with the receptor, thus their mutation doesn't alter the overall binding affinity of Tirzepatide to GIPR.	+	Structurally, as a dual agonist, <scene name='10/1037488/Tirz-bound/3'>Tirzepatide</scene> closely resembles GIP and GLP-1. The sequence alignment of all three polypeptides showcases the highly integrated nature of both GIP and GLP-1 into the amino acid sequence of Tirzepatide with very few alterations (Figure 2). [[Image:GIPGLPTirz.png\|700 px\|right\|thumb\|Figure 2. Sequence alignment of GLP-1, GIP, and Tirzepatide. Residues shown in black are found in all three amino acid sequences. Pink or red coloration denotes residues that are unique to GIP or GLP-1, respectively. The sequence of tirzepatide is colored accordingly, and residues differing from both GIP and GLP-1 are highlighted in blue. Residues that differ across all three structures are boxed.]] The <scene name='10/1037488/Gip-y1-intrxn-still/8'>conserved Tyr1</scene> residue allows for simulation of a highly similar interaction between Tirzepatide and the GIP receptor. Had this been altered, Tirzepatide would not nearly bind with as high of an affinity for GIPR. Several <scene name='10/1037488/Tirz-bound-differences/3'>unique residues in Tirzepatide</scene> do not align with either the sequence of GIP or GLP-1 and are located toward the C-terminus end of the structure. They include Ala21, Gln24, Ile27, and Gly30. The <scene name='10/1037488/Gip-differences/6'>corresponding GIP residues</scene> are Asp21, Asn24, Leu27, and Lys30. Interestingly, these residues do not interact with the receptor, thus their mutation doesn't alter the overall binding affinity of Tirzepatide to GIPR.